• Image of Vivelle-Dot medication Image of Vivelle-Dot medication

    • ESTRADIOL (TWICE WEEKLY) (Generic for VIVELLE-DOT)

    • QTY 8
    • .0375MG/24
    • PATCH TDSW
    • Near  22546

ESTRADIOL (es tra DYE ole) reduces the number and severity of hot flashes due to menopause. It may also help relieve the symptoms of menopause, such as vaginal irritation, dryness, or pain during sex. It can be used to prevent osteoporosis. It works by increasing levels of the hormone estrogen in the body. It is an estrogen hormone.

ESTRADIOL (TWICE WEEKLY) (Generic for VIVELLE-DOT) Lifestyle Interactions

  • Tipranavir 250mg, Oral capsule

    • Interaction: Grapefruit juice
    • Severity: Major
    • Notes for Consumers: Do not drink grapefruit juice or eat grapefruit while taking this medication. Grapefruit may alter the effects of your medication. Serious side effects may occur. Contact your care team right away if you experience new or worsening side effects.
    • Notes for Professionals: Advise patients to avoid grapefruit and grapefruit juice during tipranavir treatment due to the risk for increased tipranavir exposure and adverse reactions. Tipranavir is a CYP3A substrate and grapefruit juice is a CYP3A inhibitor.

  • Tipranavir 250mg, Oral capsule

    • Interaction: Cannabis
    • Severity: Major
    • Notes for Consumers: Discuss cannabis use with your care team. The effects of cannabis may be altered if used with your medication. Call emergency services right away if you experience slow or shallow breathing, shortness of breath, feeling faint, dizziness, confusion, or trouble staying awake.
    • Notes for Professionals: Advise patients to avoid cannabis use during protease inhibitor treatment. Concomitant use may alter the exposure of some cannabinoids and increase the risk for adverse reactions. The cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are CYP3A substrates and protease inhibitors are strong CYP3A inhibitors. Concomitant use of a cannabinoid product containing THC and CBD at an approximate 1:1 ratio with another strong CYP3A inhibitor increased THC, 11-OH-THC, and CBD peak exposures by 1.3-, 3-, and 1.9-fold respectively.

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.